Search
SOLACI Congress
HomeTCT 2018HIGHLIGHTS

HIGHLIGHTS

View Category
Chronic Ischemic cardiopathy

TCT 2018 | ULTIMATE: IVUS Guided DES Implantation for All Vessels, for All Lesions

Intravascular Ultrasound (IVUS) guided drug eluting stent (DES) implantation is associated with less adverse events compared against...
solaci -
Learn More
Chronic Ischemic cardiopathy

TCT 2018 | SYNTAXES: 10 Year Follow Up is ‘Trendy’

The SYNTAX trial had a 5-year follow-up, but the SYNTAXES (“ES” for extended survival) was specifically designed...
solaci -
Learn More
Chronic Ischemic cardiopathy

TCT 2018 | PREPARE-CALC: Rotational Atherectomy vs. Cutting Balloon in Calcified Lesions

Compared against conventional predilation with balloon, rotational atherectomy is associated with higher procedural success rate in severely...
solaci -
Learn More
HIGHLIGHTS

TCT 2018 | NEOPRO: A Registry for Acurate neo and Evolut PRO

The purpose of this registry was to compare short-term clinical events and echocardiographic findings in two self-expanding...
solaci -
Learn More
HIGHLIGHTS

TCT 2018 | PARTNER 2 Valve-in-Valve: Clinical and Hemodynamic Results Maintained in the Long Term

The 1-year follow-up for this study was published last year in JACC, and it showed that transcatheter...
solaci -
Learn More
Coronary disease

TCT 2018 | TALENT: Ultrathin Struts and Bioresorbable Polymer at the Lowest Possible Cost

This study assessed the Ultra-thin Strut Bioresorbable Polymer-based Coronary DES (Supraflex) against the Xience, with special emphasis...
solaci -
Learn More
Coronary disease

TCT 2018 | SORT OUT IX: Polymer-Free DES with Ultra-Thin Struts vs. Bioresorbable Polymer- Based DES

Polymer persistence in 1st and 2nd generation DES meant to allow drug release has been associated with...
solaci -
Learn More
Coronary disease

TCT 2018 | LEADERS FREE II: Polymer-Free DES in Patients at High Risk for Bleeding with 1 Month of Antiplatelet Therapy

This study was aimed at gaining device registration from the US Food and Drug Administration (FDA) for...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Institutional News

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy